Drugmakers control distribution

Eli Lilly is selling more obesity care through its own front door, not just through doctors and pharmacies. (pharmexec.com) Lilly expanded LillyDirect to offer all approved single-dose vial strengths of Zepbound, including 12.5 milligrams and 15 milligrams, through its self-pay channel. PharmExec reported the higher doses were priced at $499 a month when Lilly added them, alongside telehealth and weight-management support. (pharmexec.com) Lilly has also tied new products to that channel. After the Food and Drug Administration approved Foundayo, the company said prescriptions would be accepted immediately through LillyDirect, with shipping starting April 6, 2026, before broader retail rollout. (fda.gov) (investor.lilly.com) Foundayo is Lilly’s brand name for orforglipron, a once-daily obesity pill. The Food and Drug Administration said the April 1, 2026 approval came 50 days after filing and 294 days before the original January 20, 2027 target date under the Commissioner’s National Priority Voucher pilot. (fda.gov) The setup gives Lilly control over more of the treatment path: marketing, prescribing links, fulfillment and follow-up support. PharmExec said LillyDirect pairs medication access with telehealth and disease-management resources, reducing the role of stand-alone consumer health apps that built businesses around finding prescribers and coaching patients. (pharmexec.com 1) (pharmexec.com 2) Lilly is also using safety warnings to steer patients away from alternatives outside its supply chain. In a March 12, 2026 open letter, the company said testing found a potentially dangerous impurity in some compounded tirzepatide products mixed with vitamin B12. (pharmexec.com) (kbn.ky.gov) Compounded drugs are custom-made versions prepared by specialized pharmacies, often when branded drugs are scarce or unavailable. The Food and Drug Administration has long said compounded products are not reviewed for safety, effectiveness or quality before sale, and Lilly cited that warning in its letter. (kbn.ky.gov) (pharmexec.com) The direct channel did not appear overnight. Lilly had already partnered with telehealth companies including Teladoc Health and LifeMD to route eligible patients into full-service weight-loss programs that included lower-cost Zepbound vials. (fiercehealthcare.com) Now the company is combining fast regulatory wins, direct fulfillment and safety messaging into one distribution strategy. For patients, that means more obesity treatment may start with a drugmaker’s platform instead of an independent app or a neighborhood pharmacy. (fda.gov) (pharmexec.com)